Collaboration Opportunity between H3D & LifeArc

Collaboration Opportunity: Tackling the Challenge of AMR Together I 20th May 2026

Are you interested in advancing solutions for antimicrobial resistance (AMR)?

The Centre for Translational AMR Research (CTAR), a collaboration between H3D, Africa’s first integrated drug discovery centre based at the University of Cape Town and LifeArc, is seeking new collaborations in the antimicrobial resistance (AMR) field.

As part of our mission to accelerate the discovery and development of urgently needed antibiotics, we are inviting researchers, institutions and partners with promising chemical matter to engage with the H3D AMR team.

Focus Areas

We are particularly interested in compounds demonstrating activity against the following gram-negative ESKAPE pathogens:

Klebsiella pneumoniae (K. pneumoniae)
Acinetobacter baumannii (A. baumannii)
Pseudomonas aeruginosa (P. aeruginosa)
Escherichia coli (E. coli)

These pathogens represent some of the most critical global AMR threats and remain a major challenge in infectious disease treatment worldwide.

Collaboration Opportunity

If you have chemical matter showing activity against any of these pathogens and are interested in progressing your research through the drug discovery pipeline, we encourage you to connect with us.

The H3D AMR team offers expertise and infrastructure across the drug discovery value chain, supporting the advancement of promising candidates toward impactful therapeutic solutions.

Applications Now Open

Applications for proposals are currently open. 

Apply via the online Google Form here: 

https://forms.gle/pVWdxzdJd1TyjS2X8

Download the proposal template here: 

Please include as much information as possible in the table provided in the template. This will serve as an overview summary of your compound profile.

Kindly save the completed template using your name as reference and email your submission to: Ms Chanté Foentjies on chante.foentjies@uct.ac.za

Submission Deadline

The closing date for submissions is 19 June 2026.

Let’s accelerate solutions for AMR together.